@article{10.11648/j.ijcocr.20251004.11,
  author = {Berthe Sabine Esson Mapoko and Esther Dina Bell and Veronique Batoum Mboua and Kenn Chi Ndi and Etienne Atenguena and Dominique Anaba and Lionel Tabola and Pelagie Douanla and Anne Sango and Ruth Mapenya and Anne Marthe Maison and Sidonie Ananga and Ambroise Ntama and Zacharie Sando and Paul Ndom},
  title = {Epidemiological, Clinical, and Therapeutic Profile of Long-term Breast Cancer Survivors in Cameroon: A Retrospective Cohort Study
},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  volume = {10},
  number = {4},
  pages = {127-134},
  doi = {10.11648/j.ijcocr.20251004.11},
  url = {https://doi.org/10.11648/j.ijcocr.20251004.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20251004.11},
  abstract = {Introduction: Breast cancer (BC) is a major public health challenge in Sub-Saharan Africa (SSA) due to late diagnosis and low survival. Studying "long-term survivors" is essential to identifying resilience factors and successful strategies. This study aims to describe the epidemiological, clinical, and therapeutic characteristics of long-term breast cancer survivors at the Yaounde General Hospital (YGH) in Cameroon and and identify factors associated with prolonged survival. Methods: In this retrospective cohort study (2008–2018), we analyzed 204 patient records. Long-term survivors were defined as the 68 patients (33.3% of the cohort) who survived for at least three years after their diagnosis. Data were collected using a standardized questionnaire. Descriptive statistics were used to detail their profile. Prognostic factors were identified using a Cox regression model. Results: The cohort was predominantly female (98.5%), with a median overall survival of 73.92 months (6.16 years). Patients were typically diagnosed at earlier stages (IIA, IIB, IIIA), and signs of locally advanced disease were rare. Key prognostic factors included (OR = 8.3, pConclusion: Long-term survivors are characterized by less aggressive initial presentation and access to complete, multimodal treatment. Prioritizing early diagnosis and continuous oncological follow-up is key to improving regional prognosis.
},
 year = {2025}
}

Copy | Download

TY  - JOUR
T1  - Epidemiological, Clinical, and Therapeutic Profile of Long-term Breast Cancer Survivors in Cameroon: A Retrospective Cohort Study

AU  - Berthe Sabine Esson Mapoko
AU  - Esther Dina Bell
AU  - Veronique Batoum Mboua
AU  - Kenn Chi Ndi
AU  - Etienne Atenguena
AU  - Dominique Anaba
AU  - Lionel Tabola
AU  - Pelagie Douanla
AU  - Anne Sango
AU  - Ruth Mapenya
AU  - Anne Marthe Maison
AU  - Sidonie Ananga
AU  - Ambroise Ntama
AU  - Zacharie Sando
AU  - Paul Ndom
Y1  - 2025/12/03
PY  - 2025
N1  - https://doi.org/10.11648/j.ijcocr.20251004.11
DO  - 10.11648/j.ijcocr.20251004.11
T2  - International Journal of Clinical Oncology and Cancer Research
JF  - International Journal of Clinical Oncology and Cancer Research
JO  - International Journal of Clinical Oncology and Cancer Research
SP  - 127
EP  - 134
PB  - Science Publishing Group
SN  - 2578-9511
UR  - https://doi.org/10.11648/j.ijcocr.20251004.11
AB  - Introduction: Breast cancer (BC) is a major public health challenge in Sub-Saharan Africa (SSA) due to late diagnosis and low survival. Studying "long-term survivors" is essential to identifying resilience factors and successful strategies. This study aims to describe the epidemiological, clinical, and therapeutic characteristics of long-term breast cancer survivors at the Yaounde General Hospital (YGH) in Cameroon and and identify factors associated with prolonged survival. Methods: In this retrospective cohort study (2008–2018), we analyzed 204 patient records. Long-term survivors were defined as the 68 patients (33.3% of the cohort) who survived for at least three years after their diagnosis. Data were collected using a standardized questionnaire. Descriptive statistics were used to detail their profile. Prognostic factors were identified using a Cox regression model. Results: The cohort was predominantly female (98.5%), with a median overall survival of 73.92 months (6.16 years). Patients were typically diagnosed at earlier stages (IIA, IIB, IIIA), and signs of locally advanced disease were rare. Key prognostic factors included (OR = 8.3, pConclusion: Long-term survivors are characterized by less aggressive initial presentation and access to complete, multimodal treatment. Prioritizing early diagnosis and continuous oncological follow-up is key to improving regional prognosis.

VL  - 10
IS  - 4
ER  - 

Copy | Download